Scilex Holding (SCLXW) EPS (Weighted Average and Diluted) Growth (3y) (2023 - 2026)
Scilex Holding (SCLXW) EPS (Weighted Average and Diluted) Growth (3y) (2023 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EPS (Weighted Avg. Diluted) Growth (3y) (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
- |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
76.98% |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
318.57% |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
44.22% |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
-52.54% |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
-14.16% |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
26.25% |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
-21.46% |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
6.98% |
| 10 |
Scilex Holding |
- |
- |
4.15 Mn |
-205.62% |
| Date | Value |
|---|
| Mar 31, 2026 |
-205.62% |
| Dec 31, 2025 |
-228.30% |
| Sep 30, 2025 |
-419.94% |
| Jun 30, 2025 |
-285.02% |
| Mar 31, 2025 |
-218.42% |
| Dec 31, 2024 |
110.00% |
| Sep 30, 2024 |
-93.54% |
| Jun 30, 2024 |
-815.37% |
| Mar 31, 2024 |
-185.86% |
| Dec 31, 2023 |
-74.28% |
| Jun 30, 2023 |
96.64% |
| Mar 31, 2023 |
96.47% |
